While our understanding of autoreactive T cells in T1D has grown, a cure remains out of reach, and the initial triggers of the autoimmune attack are still unknown. The only disease-modifying therapy, teplizumab, offers a delay but broadly impacts all T cells. Our innovative research into Dual Expressers (DEs) has yielded a unique antibody that, when administered in a tolerogenic form, demonstrated disease reversal in preclinical studies. We are committed to advancing this targeted approach towards clinical trials and a potential cure for T1D.
